A case of onychomycosis caused by a terbinafine-susceptible Fusarium solani in Vietnam
-
Thi Minh Chau Ngo
,
Phuong Anh Ton Nu
,
Le Chi Cao
,
Thi Ngoc Thuy Ha
,
Thi Bich Thao Do
,
Giang Tran Thi
Abstract
Fusarium spp. are the common onychomycosis pathogens in non-dermatophyte molds, and are considered resistant to many antifungal agents. We reported onychomycosis of the fingernail caused by Fusarium solani in Vietnam. The minimum inhibitory concentration of terbinafine against the tested isolate was 1µg/ml, which was the lowest of all antimycotic agents. The patient was successfully treated with a daily dose of 250mg terbinafine for two months, and no recurrence occurred after a one-year follow-up. Antifungal susceptibility testing is recommended in Fusarium onychomycosis.
1. Gupta AK, Stec N, Summerbell RC, Shear NH, Piguet V, Tosti A, et al. Onychomycosis: a review. J Eur Acad Dermatol Venereol 2020; 34: 1972-1990.
2. Uemura EVG, Barbosa MDS, Simionatto S, Al-Harrasi A, Al-Hatmi AMS, Rossato L. Onychomycosis caused by Fusarium species. J Fungi (Basel) 2022; 8: 360.
3. Chadeganipour M, Mohammadi R. Causative agents of onychomycosis: a 7-year study. J Clin Lab Anal 2016; 30: 1013-1020.
4. Noguchi H, Matsumoto T, Kimura U, Hiruma M, Kano R, Yaguchi T, et al. Non-dermatophyte Mould Onychomycosis in Japan. Med Mycol J 2020; 61: 23-31.
5. Ribeiro CSDC, Zaitz C, Framil VMDS, Ottoboni TSDC, Tonoli MSDC, Ribeiro RP. Descriptive study of onychomycosis in a hospital in São Paulo. Braz J Microbiol 2015; 46: 485-492.
6. Haghani I, Shams-Ghahfarokhi M, Dalimi Asl A, Shokohi T, Hedayati MT. Molecular identification and antifungal susceptibility of clinical fungal isolates from onychomycosis (uncommon and emerging species). Mycoses 2019; 62: 128-143.
7. Gupta AK, Summerbell RC, Venkataraman M, Quinlan EM. Nondermatophyte mould onychomycosis. J Eur Acad Dermatol Venereol 2021; 35: 1628-1641.
8. Diongue K, Ndiaye M, Seck MC, Diallo MA, Badiane AS, Ndiaye D. Onychomycosis caused by Fusarium spp. in Dakar, Senegal: epidemiological, clinical, and mycological study. Dermatol Res Pract 2017; 2017: 1268130.
9. Batista BG, Chaves MAD, Reginatto P, Saraiva OJ, Fuentefria AM. Human fusariosis: An emerging infection that is difficult to treat. Rev Soc Bras Med Trop 2020; 53: e20200013.
10. Hof H. The medical relevance of Fusarium spp. J Fungi (Basel) 2020; 6: 117.
11. Ngo TMC, Ton Nu PA, Le CC, Vo MT, Ha TNT, Do TBT, et al. Nannizzia incurvata in Hue city - Viet Nam: Molecular identification and antifungal susceptibility testing. J Mycol Med 2022; 32: 101291.
12. Guinea J, Meletiadis J, Arikan-Akdagli S, Muehlethaler K, Kahlmeter G, Arendrup M, et al. EUCAST definitive document E.Def 9.4 Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. EUCAST 2022. https://www.eucast.org/astoffungi/methodsinantifungalsusceptibilitytesting/ast_of_moulds
13. Rosa PD, Heidrich D, Corrêa C, Scroferneker ML, Vettorato G, Fuentefria AM, et al. Genetic diversity and antifungal susceptibility of Fusarium isolates in onychomycosis. Mycoses 2017; 60: 616-622.
14. Byrne JP, Boss JM, Dawber RP. Contraceptive pill-induced porphyria cutanea tarda presenting with onycholysis of the finger nails. Postgrad Med J 1976; 52: 535-538.
15. Sav H, Rafati H, Öz Y, Dalyan-Cilo B, Ener B, Mohammadi F, et al. Biofilm formation and resistance to fungicides in clinically relevant members of the fungal genus Fusarium. J Fungi (Basel) 2018; 4: 16.
16. Galletti J, Tobaldini-Valerio FK, Silva S, Kioshima ÉS, Trierveiler-Pereira L, Bruschi M, et al. Antibiofilm activity of propolis extract on Fusarium species from onychomycosis. Future Microbiol 2017; 12: 1311-1321.
2. Uemura EVG, Barbosa MDS, Simionatto S, Al-Harrasi A, Al-Hatmi AMS, Rossato L. Onychomycosis caused by Fusarium species. J Fungi (Basel) 2022; 8: 360.
3. Chadeganipour M, Mohammadi R. Causative agents of onychomycosis: a 7-year study. J Clin Lab Anal 2016; 30: 1013-1020.
4. Noguchi H, Matsumoto T, Kimura U, Hiruma M, Kano R, Yaguchi T, et al. Non-dermatophyte Mould Onychomycosis in Japan. Med Mycol J 2020; 61: 23-31.
5. Ribeiro CSDC, Zaitz C, Framil VMDS, Ottoboni TSDC, Tonoli MSDC, Ribeiro RP. Descriptive study of onychomycosis in a hospital in São Paulo. Braz J Microbiol 2015; 46: 485-492.
6. Haghani I, Shams-Ghahfarokhi M, Dalimi Asl A, Shokohi T, Hedayati MT. Molecular identification and antifungal susceptibility of clinical fungal isolates from onychomycosis (uncommon and emerging species). Mycoses 2019; 62: 128-143.
7. Gupta AK, Summerbell RC, Venkataraman M, Quinlan EM. Nondermatophyte mould onychomycosis. J Eur Acad Dermatol Venereol 2021; 35: 1628-1641.
8. Diongue K, Ndiaye M, Seck MC, Diallo MA, Badiane AS, Ndiaye D. Onychomycosis caused by Fusarium spp. in Dakar, Senegal: epidemiological, clinical, and mycological study. Dermatol Res Pract 2017; 2017: 1268130.
9. Batista BG, Chaves MAD, Reginatto P, Saraiva OJ, Fuentefria AM. Human fusariosis: An emerging infection that is difficult to treat. Rev Soc Bras Med Trop 2020; 53: e20200013.
10. Hof H. The medical relevance of Fusarium spp. J Fungi (Basel) 2020; 6: 117.
11. Ngo TMC, Ton Nu PA, Le CC, Vo MT, Ha TNT, Do TBT, et al. Nannizzia incurvata in Hue city - Viet Nam: Molecular identification and antifungal susceptibility testing. J Mycol Med 2022; 32: 101291.
12. Guinea J, Meletiadis J, Arikan-Akdagli S, Muehlethaler K, Kahlmeter G, Arendrup M, et al. EUCAST definitive document E.Def 9.4 Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. EUCAST 2022. https://www.eucast.org/astoffungi/methodsinantifungalsusceptibilitytesting/ast_of_moulds
13. Rosa PD, Heidrich D, Corrêa C, Scroferneker ML, Vettorato G, Fuentefria AM, et al. Genetic diversity and antifungal susceptibility of Fusarium isolates in onychomycosis. Mycoses 2017; 60: 616-622.
14. Byrne JP, Boss JM, Dawber RP. Contraceptive pill-induced porphyria cutanea tarda presenting with onycholysis of the finger nails. Postgrad Med J 1976; 52: 535-538.
15. Sav H, Rafati H, Öz Y, Dalyan-Cilo B, Ener B, Mohammadi F, et al. Biofilm formation and resistance to fungicides in clinically relevant members of the fungal genus Fusarium. J Fungi (Basel) 2018; 4: 16.
16. Galletti J, Tobaldini-Valerio FK, Silva S, Kioshima ÉS, Trierveiler-Pereira L, Bruschi M, et al. Antibiofilm activity of propolis extract on Fusarium species from onychomycosis. Future Microbiol 2017; 12: 1311-1321.
| Files | ||
| Issue | Vol 14 No 6 (2022) | |
| Section | Case Report(s) | |
| DOI | https://doi.org/10.18502/ijm.v14i6.11269 | |
| Keywords | ||
| Onychomycosis; Fusarium solani; Terbinafine susceptible; Antifungal susceptibility testing; Onychomycosis treatment | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Ngo TMC, Ton Nu PA, Cao LC, Ha TNT, Do TBT, Tran Thi G. A case of onychomycosis caused by a terbinafine-susceptible Fusarium solani in Vietnam. Iran J Microbiol. 2022;14(6):932-936.
